Loading...
Anavex Life Sciences reported its financial results for the fiscal year ended September 30, 2020, highlighting significant progress across its portfolio, including positive trial results for ANAVEX®2-73 in Rett syndrome and Parkinson's disease dementia.
Positive, placebo-controlled, U.S. ANAVEX®2-73 (blarcamesine) Rett syndrome trial.
Positive Parkinson’s disease dementia trial.
Further progress in Alzheimer’s disease.
Key milestones expected from multiple programs.
Anavex anticipates key milestones from multiple programs.
Analyze how earnings announcements historically affect stock price performance